Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
Glycogen synthase kinase-3 (GSK3) inhibitors induce differentiation and growth inhibition of acute myeloid leukemia (AML) cells. Our pre-clinical studies showed GSK3 inhibition leads to sensitization of AML cells to tretinoin-mediated differentiation. We conducted a phase I trial of lithium, a GSK3...
Main Authors: | Masumi Ueda, Tammy Stefan, Lindsay Stetson, James J. Ignatz-Hoover, Benjamin Tomlinson, Richard J. Creger, Brenda Cooper, Hillard M. Lazarus, Marcos de Lima, David N. Wald, Paolo F. Caimi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00327/full |
Similar Items
-
New insight into the immunomodulatory mechanisms of Tretinoin in NMRI mice
by: Seyyed Meysam Abtahi Froushani, et al.
Published: (2014-09-01) -
High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure
by: Morgan B. Smith, et al.
Published: (2014-01-01) -
The Comparison of the Effect of Chemical Peeling with Tretinoin 1% and Glycolic Acid 70% on the Treatment of Melasma in Women
by: Guita Faghihi, et al.
Published: (2011-03-01) -
Fabrication and characterization of tretinoin-loaded nanofiber for topical skin delivery
by: Saba Khoshbakht, et al.
Published: (2020-03-01) -
Efficacy and tolerability of 0.1% tazarotene cream and 0.05% tretinoin cream in the treatment of acne vulgaris
by: Mohammad Habibur Rahman, et al.
Published: (2016-07-01)